Mizuho set a $128.00 price target on Celgene (NASDAQ:CELG) in a research note released on Friday, January 5th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
CELG has been the topic of a number of other research reports. Royal Bank of Canada cut their price target on shares of Celgene from $166.00 to $148.00 and set a top pick rating on the stock in a research note on Friday, October 27th. Leerink Swann reaffirmed a buy rating and set a $156.00 price target on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley cut their price target on shares of Celgene from $120.00 to $115.00 and set an underweight rating on the stock in a research note on Monday, October 23rd. SunTrust Banks cut their target price on shares of Celgene from $156.00 to $127.00 and set a buy rating on the stock in a research note on Friday, October 27th. Finally, William Blair reissued an outperform rating on shares of Celgene in a research note on Friday, October 20th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $131.18.
Celgene (NASDAQ CELG) opened at $106.00 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market cap of $83,460.00, a P/E ratio of 25.00, a price-to-earnings-growth ratio of 0.67 and a beta of 1.77. Celgene has a one year low of $94.55 and a one year high of $147.17.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.58 earnings per share. equities analysts expect that Celgene will post 6.69 EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. grew its holdings in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI grew its holdings in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares in the last quarter. Robecosam AG acquired a new position in Celgene during the 3rd quarter worth $114,000. Guidant Wealth Advisors acquired a new position in Celgene during the 3rd quarter worth $119,000. Finally, Capital Bank & Trust Co grew its holdings in Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares in the last quarter. 79.74% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/celgene-celg-given-a-128-00-price-target-by-mizuho-analysts.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.